Aclaris Therapeutis (ACRS): Eskata and Pipeline Should Drive Shares Higher - Cantor Fitzgerald

March 12, 2018 11:19 AM

Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $50 price target on Aclaris Therapeutis (NASDAQ: ACRS), saying Eskata ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found